In silico resources to assist in the development and evaluation of physiologically-based kinetic models

Abstract Since their inception in pharmaceutical applications, physiologically-based kinetic (PBK) models are increasingly being used across a range of sectors, such as safety assessment of cosmetics, food additives, consumer goods, pesticides and other chemicals. Such models can be used to construct organ-level concentration-time profiles of xenobiotics. These models are essential in determining the overall internal exposure to a chemical and hence its ability to elicit a biological response. There are a multitude of in silico resources available to assist in the construction and evaluation of PBK models. An overview of these resources is presented herein, encompassing all attributes required for PBK modelling. These include predictive tools and databases for physico-chemical properties and absorption, distribution, metabolism and elimination (ADME) related properties. Data sources for existing PBK models, bespoke PBK software and generic software that can assist in model development are also identified. On-going efforts to harmonise approaches to PBK model construction, evaluation and reporting that would help increase the uptake and acceptance of these models are also discussed.

[1]  Yu-Mei Tan,et al.  Challenges Associated With Applying Physiologically Based Pharmacokinetic Modeling for Public Health Decision-Making , 2018, Toxicological sciences : an official journal of the Society of Toxicology.

[2]  Eric J Martin,et al.  Physiologically Based Pharmacokinetic Modeling in Lead Optimization. 1. Evaluation and Adaptation of GastroPlus To Predict Bioavailability of Medchem Series. , 2018, Molecular pharmaceutics.

[3]  Ovanes G Mekenyan,et al.  The OECD QSAR Toolbox Starts Its Second Decade. , 2018, Methods in molecular biology.

[4]  Andrew P. Worth,et al.  EURL ECVAM strategy for achieving 3Rs impact in the assessment of toxicokinetics and systemic toxicity , 2015 .

[5]  Andreas A Linninger,et al.  Interspecies scaling in pharmacokinetics: a novel whole-body physiologically based modeling framework to discover drug biodistribution mechanisms in vivo. , 2012, Journal of pharmaceutical sciences.

[6]  A Nordmark,et al.  Physiologically Based Models in Regulatory Submissions: Output From the ABPI/MHRA Forum on Physiologically Based Modeling and Simulation , 2015, CPT: pharmacometrics & systems pharmacology.

[7]  Umair Aslam,et al.  Meta-Analysis of the Turnover of Intestinal Epithelia in Preclinical Animal Species and Humans , 2014, Drug Metabolism and Disposition.

[8]  Kristoffer Andersson,et al.  Maxsim2 - Real-time interactive simulations for computer-assisted teaching of pharmacokinetics and pharmacodynamics , 2014, Comput. Methods Programs Biomed..

[9]  David S. Wishart,et al.  DrugBank 5.0: a major update to the DrugBank database for 2018 , 2017, Nucleic Acids Res..

[10]  Hugh A. Barton,et al.  Data for Physiologically Based Pharmacokinetic Modeling in Neonatal Animals: Physiological Parameters in Mice and Sprague-Dawley Rats , 2004 .

[11]  Nina Jeliazkova,et al.  Toxmatch--a chemical classification and activity prediction tool based on similarity measures. , 2008, Regulatory toxicology and pharmacology : RTP.

[12]  Jie Li,et al.  admetSAR 2.0: web‐service for prediction and optimization of chemical ADMET properties , 2018, Bioinform..

[13]  Douglas E. V. Pires,et al.  pkCSM: Predicting Small-Molecule Pharmacokinetic and Toxicity Properties Using Graph-Based Signatures , 2015, Journal of medicinal chemistry.

[14]  L. Lamon,et al.  Physiologically based mathematical models of nanomaterials for regulatory toxicology: A review , 2019, Computational toxicology.

[15]  P. Carrupt,et al.  Molecular fields in quantitative structure–permeation relationships: the VolSurf approach , 2000 .

[16]  Amin Rostami-Hodjegan,et al.  Changes in liver volume from birth to adulthood: A meta‐analysis , 2005, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[17]  Samiul Hasan,et al.  ADME SARfari: comparative genomics of drug metabolizing systems , 2015, Bioinform..

[18]  K Rowland-Yeo,et al.  Basic Concepts in Physiologically Based Pharmacokinetic Modeling in Drug Discovery and Development , 2013, CPT: pharmacometrics & systems pharmacology.

[19]  K R Przybylak,et al.  Characterisation of data resources for in silico modelling: benchmark datasets for ADME properties , 2018, Expert opinion on drug metabolism & toxicology.

[20]  Olivier Michielin,et al.  SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules , 2017, Scientific Reports.

[21]  Daniel T. Chang,et al.  Developing a Physiologically-Based Pharmacokinetic Model Knowledgebase in Support of Provisional Model Construction , 2016, PLoS Comput. Biol..

[22]  Ruifeng Liu,et al.  vNN Web Server for ADMET Predictions , 2017, Front. Pharmacol..

[23]  Isabelle Ragueneau-Majlessi,et al.  A useful tool for drug interaction evaluation: The University of Washington Metabolism and Transport Drug Interaction Database , 2010, Human Genomics.

[24]  Antony J. Williams,et al.  The CompTox Chemistry Dashboard: a community data resource for environmental chemistry , 2017, Journal of Cheminformatics.

[25]  E Benfenati,et al.  ToxRead: A tool to assist in read across and its use to assess mutagenicity of chemicals£ , 2014, SAR and QSAR in environmental research.

[26]  Bas J Blaauboer,et al.  Evaluation of research activities and research needs to increase the impact and applicability of alternative testing strategies in risk assessment practice. , 2011, Regulatory toxicology and pharmacology : RTP.

[27]  C Cobelli,et al.  SAAM II: Simulation, Analysis, and Modeling Software for tracer and pharmacokinetic studies. , 1998, Metabolism: clinical and experimental.

[28]  Jochem Louisse,et al.  Use of Physiologically Based Kinetic Modeling-Based Reverse Dosimetry to Predict in Vivo Toxicity from in Vitro Data. , 2017, Chemical research in toxicology.

[29]  Karen Blackburn,et al.  Structure activity relationship (SAR) toxicological assessments: The role of expert judgment , 2018, Regulatory toxicology and pharmacology : RTP.

[30]  Hugh A. Barton,et al.  Database for Physiologically Based Pharmacokinetic (PBPK) Modeling: Physiological Data for Healthy and Health-Impaired Elderly , 2009, Journal of toxicology and environmental health. Part B, Critical reviews.

[31]  Ke Liu,et al.  ADMETNet: The knowledge base of pharmacokinetics and toxicology network. , 2017, Journal of genetics and genomics = Yi chuan xue bao.

[32]  F. Williams,et al.  EDETOX. Evaluations and predictions of dermal absorption of toxic chemicals , 2004, International archives of occupational and environmental health.

[33]  Antony J. Williams,et al.  ChemSpider:: An Online Chemical Information Resource , 2010 .

[34]  Piet H. Van Der Graaf,et al.  A4S: A user-friendly graphical tool for pharmacokinetic and pharmacodynamic (PK/PD) simulation , 2013, Comput. Methods Programs Biomed..

[35]  Robert J. Bauer,et al.  A survey of population analysis methods and software for complex pharmacokinetic and pharmacodynamic models with examples , 2007, The AAPS Journal.

[36]  Ruedi Aebersold,et al.  Quantitative ADME Proteomics – CYP and UGT Enzymes in the Beagle Dog Liver and Intestine , 2014, Pharmaceutical Research.

[37]  Ian Cousins,et al.  Development and application of a generalized physiologically based pharmacokinetic model for multiple environmental contaminants , 2003, Environmental toxicology and chemistry.

[38]  Saskia Preissner,et al.  The Transformer database: biotransformation of xenobiotics , 2013, Nucleic Acids Res..

[39]  Helle Holst,et al.  Excipients in Neonatal Medicinal Products: Never Prescribed, Commonly Administered , 2018, Pharmaceutical Medicine.

[40]  Bas J Blaauboer,et al.  Evaluation of simple in vitro to in vivo extrapolation approaches for environmental compounds. , 2014, Toxicology in vitro : an international journal published in association with BIBRA.

[41]  Alexander Tropsha,et al.  Trust, But Verify: On the Importance of Chemical Structure Curation in Cheminformatics and QSAR Modeling Research , 2010, J. Chem. Inf. Model..

[42]  M Jamei,et al.  Development of a Multicompartment Permeability-Limited Lung PBPK Model and Its Application in Predicting Pulmonary Pharmacokinetics of Antituberculosis Drugs , 2015, CPT: pharmacometrics & systems pharmacology.

[43]  Jie Shen,et al.  admetSAR: A Comprehensive Source and Free Tool for Assessment of Chemical ADMET Properties , 2012, J. Chem. Inf. Model..

[44]  R J Keizer,et al.  Modeling and Simulation Workbench for NONMEM: Tutorial on Pirana, PsN, and Xpose , 2013, CPT: pharmacometrics & systems pharmacology.

[45]  Masoud Jamei,et al.  Fetal Physiologically Based Pharmacokinetic Models: Systems Information on the Growth and Composition of Fetal Organs , 2018, Clinical Pharmacokinetics.

[46]  L Li,et al.  Organ Impairment—Drug–Drug Interaction Database: A Tool for Evaluating the Impact of Renal or Hepatic Impairment and Pharmacologic Inhibition on the Systemic Exposure of Drugs , 2015, CPT: pharmacometrics & systems pharmacology.

[47]  Santiago Vilar,et al.  Medicinal chemistry and the molecular operating environment (MOE): application of QSAR and molecular docking to drug discovery. , 2008, Current topics in medicinal chemistry.

[48]  Kostas Kostarelos,et al.  Physiologically based pharmacokinetic modeling of nanoparticles. , 2010, ACS nano.

[49]  Jianghong Fan,et al.  Physiologically Based Pharmacokinetic Modeling of Nanoparticles. , 2019, Journal of pharmaceutical sciences.

[50]  Yiqun Cao,et al.  ChemMine tools: an online service for analyzing and clustering small molecules , 2011, Nucleic Acids Res..

[51]  George Loizou,et al.  Development of good modelling practice for physiologically based pharmacokinetic models for use in risk assessment: the first steps. , 2008, Regulatory toxicology and pharmacology : RTP.

[52]  Xin Chen,et al.  ADME-AP: a database of ADME associated proteins , 2002, Bioinform..

[53]  A Rostami-Hodjegan,et al.  Physiologically Based Pharmacokinetics Is Impacting Drug Development and Regulatory Decision Making , 2015, CPT: pharmacometrics & systems pharmacology.

[54]  Sabina Podlewska,et al.  MetStabOn—Online Platform for Metabolic Stability Predictions , 2018, International journal of molecular sciences.

[55]  Michael R Berthold,et al.  KNIME for reproducible cross-domain analysis of life science data. , 2017, Journal of biotechnology.

[56]  A Worth,et al.  Next generation physiologically based kinetic (NG-PBK) models in support of regulatory decision making , 2019, Computational toxicology.

[57]  Johann Gasteiger,et al.  New Publicly Available Chemical Query Language, CSRML, To Support Chemotype Representations for Application to Data Mining and Modeling , 2015, J. Chem. Inf. Model..

[58]  T W Schultz,et al.  A strategy for structuring and reporting a read-across prediction of toxicity. , 2015, Regulatory toxicology and pharmacology : RTP.

[59]  Marco Andrello,et al.  MetaPopGen: an r package to simulate population genetics in large size metapopulations , 2015, Molecular ecology resources.

[60]  Judith C. Madden,et al.  In silico prediction of skin metabolism and its implication in toxicity assessment , 2017 .

[61]  Nicolas Le Novère,et al.  BioModels Database: a repository of mathematical models of biological processes. , 2013, Methods in molecular biology.

[62]  Tingjun Hou,et al.  ADME evaluation in drug discovery , 2002, Journal of molecular modeling.

[63]  Amin Rostami-Hodjegan,et al.  Anatomical, Physiological and Metabolic Changes with Gestational Age during Normal Pregnancy , 2012, Clinical Pharmacokinetics.

[64]  Alicia Paini,et al.  Finding synergies for 3Rs – Toxicokinetics and read‐across: Report from an EPAA partners' Forum , 2018, Regulatory toxicology and pharmacology : RTP.

[65]  Paul S Price,et al.  Modeling Interindividual Variation in Physiological Factors Used in PBPK Models of Humans , 2003, Critical reviews in toxicology.

[66]  S. Polak,et al.  Physiologically based pharmacokinetic modelling to guide drug delivery in older people , 2018, Advanced drug delivery reviews.

[67]  S D Dimitrov,et al.  QSAR Toolbox – workflow and major functionalities* , 2016, SAR and QSAR in environmental research.

[68]  Shiew-Mei Huang,et al.  Application of Physiologically Based Pharmacokinetic (PBPK) Modeling to Support Dose Selection: Report of an FDA Public Workshop on PBPK , 2015, CPT: pharmacometrics & systems pharmacology.

[69]  M. Delp,et al.  Physiological Parameter Values for Physiologically Based Pharmacokinetic Models , 1997, Toxicology and industrial health.

[70]  Henri Xhaard,et al.  IDAAPM: integrated database of ADMET and adverse effects of predictive modeling based on FDA approved drug data , 2016, Journal of Cheminformatics.

[71]  L Zhang,et al.  Applications of Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation During Regulatory Review , 2011, Clinical pharmacology and therapeutics.

[72]  K. Giacomini,et al.  The UCSF‐FDA TransPortal: A Public Drug Transporter Database , 2012, Clinical pharmacology and therapeutics.

[73]  Igor V. Tetko,et al.  Online chemical modeling environment (OCHEM): web platform for data storage, model development and publishing of chemical information , 2011, J. Comput. Aided Mol. Des..

[74]  Gang Fu,et al.  PubChem Substance and Compound databases , 2015, Nucleic Acids Res..

[75]  Andrew Worth,et al.  Investigating the state of physiologically based kinetic modelling practices and challenges associated with gaining regulatory acceptance of model applications , 2017, Regulatory toxicology and pharmacology : RTP.

[76]  Glenn J. Myatt,et al.  LeadScope: Software for Exploring Large Sets of Screening Data , 2000, J. Chem. Inf. Comput. Sci..

[77]  K. Bischoff,et al.  Methotrexate pharmacokinetics. , 1971, Journal of pharmaceutical sciences.

[78]  Lu Gaohua,et al.  Development of a permeability-limited model of the human brain and cerebrospinal fluid (CSF) to integrate known physiological and biological knowledge: Estimating time varying CSF drug concentrations and their variability using in vitro data. , 2016, Drug metabolism and pharmacokinetics.

[79]  Iraj Hosseini,et al.  gPKPDSim: a SimBiology®-based GUI application for PKPD modeling in drug development , 2018, Journal of Pharmacokinetics and Pharmacodynamics.

[80]  Andreas Bender,et al.  Metrabase: a cheminformatics and bioinformatics database for small molecule transporter data analysis and (Q)SAR modeling , 2015, Journal of Cheminformatics.

[81]  Sebastian Polak,et al.  A four-compartment PBPK heart model accounting for cardiac metabolism - model development and application , 2017, Scientific reports.

[82]  Sebastian Polak,et al.  Prediction of concentration-time profile and its inter-individual variability following the dermal drug absorption. , 2012, Journal of pharmaceutical sciences.

[83]  Alicia Paini,et al.  In vitro to in vivo extrapolation for high throughput prioritization and decision making. , 2018, Toxicology in vitro : an international journal published in association with BIBRA.

[84]  Corie A Ellison,et al.  Structural and functional pharmacokinetic analogs for physiologically based pharmacokinetic (PBPK) model evaluation , 2018, Regulatory toxicology and pharmacology : RTP.

[85]  L. Görlitz,et al.  Development of Physiologically Based Organ Models to Evaluate the Pharmacokinetics of Drugs in the Testes and the Thyroid Gland , 2017, CPT: pharmacometrics & systems pharmacology.

[86]  E. Niclas Jonsson,et al.  Perl-speaks-NONMEM (PsN) - a Perl module for NONMEM related programming , 2004, Comput. Methods Programs Biomed..

[87]  Amin Rostami-Hodjegan,et al.  Fetal Physiologically-Based Pharmacokinetic Models: Systems Information on Fetal Biometry and Gross Composition , 2018, Clinical Pharmacokinetics.

[88]  Tingting Fu,et al.  Therapeutic target database update 2018: enriched resource for facilitating bench-to-clinic research of targeted therapeutics , 2017, Nucleic Acids Res..

[89]  Y Sakuratani,et al.  Hazard Evaluation Support System (HESS) for predicting repeated dose toxicity using toxicological categories , 2013, SAR and QSAR in environmental research.

[90]  Dong-Sheng Cao,et al.  ADMETlab: a platform for systematic ADMET evaluation based on a comprehensively collected ADMET database , 2018, Journal of Cheminformatics.

[91]  Antje Chang,et al.  BRENDA in 2019: a European ELIXIR core data resource , 2018, Nucleic Acids Res..

[92]  François Bouzom,et al.  Physiologically Based Pharmacokinetic Modelling of Drug Penetration Across the Blood–Brain Barrier—Towards a Mechanistic IVIVE-Based Approach , 2013, The AAPS Journal.

[93]  Sebastian Polak,et al.  Plasma vs heart tissue concentration in humans - literature data analysis of drugs distribution. , 2015, Biopharmaceutics & drug disposition.

[94]  N. Ozawa,et al.  Transporter Database, TP-Search: A Web-Accessible Comprehensive Database for Research in Pharmacokinetics of Drugs , 2004, Pharmaceutical Research.

[95]  Anne Hersey,et al.  A large-scale dataset of in vivo pharmacology assay results , 2018, Scientific Data.

[96]  Stefan Kramer,et al.  CheS-Mapper 2.0 for visual validation of (Q)SAR models , 2014, Journal of Cheminformatics.

[97]  Hannah M Jones,et al.  Predicting pharmacokinetic profiles using in silico derived parameters. , 2013, Molecular pharmaceutics.

[98]  A. Krause,et al.  Visualization and Communication of Pharmacometric Models With Berkeley Madonna , 2014, CPT: pharmacometrics & systems pharmacology.

[99]  R. Badhan,et al.  Development of a Region-Specific Physiologically Based Pharmacokinetic Brain Model to Assess Hippocampus and Frontal Cortex Pharmacokinetics , 2018, Pharmaceutics.